Voeller, Julie Erbe, Amy K. Slowinski, Jacob Rasmussen, Kayla Carlson, Peter M. Hoefges, Anna VandenHeuvel, Sabrina Stuckwisch, Ashley Wang, Xing Gillies, Stephen D.
...
Published in
Journal for ImmunoTherapy of Cancer
BackgroundUnlike some adult cancers, most pediatric cancers are considered immunologically cold and generally less responsive to immunotherapy. While immunotherapy has already been incorporated into standard of care treatment for pediatric patients with high-risk neuroblastoma, overall survival remains poor. In a mouse melanoma model, we found that...
Bagacean, Cristina Tempescul, Adrian Ternant, David Banet, Anne Douet-Guilbert, Nathalie Bordron, Anne Bendaoud, Boutahar Saad, Hussam Zdrenghea, Mihnea Berthou, Christian
...
Published in
Journal for ImmunoTherapy of Cancer
Chronic lymphocytic leukemia (CLL) is the most common type of leukemia and the anti-CD20 monoclonal antibody, rituximab, represents the therapeutic gold standard for more than 2 decades in this pathology, when used in combination with chemotherapy. However, some patients experience treatment resistance or rapid relapses, and in particular, those ha...
Qayyum, Aliya Hwang, Ken-Pin Stafford, Jason Verma, Anuj Maru, Dipen M. Sandesh, Subramanya Sun, Jia Pestana, Roberto Carmagnani Avritscher, Rony Hassan, Manal M.
...
Published in
Journal for ImmunoTherapy of Cancer
BackgroundCurrently, there are no imaging predictors of immunotherapy outcome in hepatocellular carcinoma (HCC). The study aim was to determine if stiffness changes measured by magnetic resonance elastography (MRE) can be a predictor of immunotherapy response in patients with advanced HCC.Materials and methodsThis was a prospective study of 15 pati...
Torres Chavez, Alejandro McKenna, Mary Kathryn Canestrari, Emanuele Dann, Christina T. Ramos, Carlos A. Lulla, Premal Leen, Ann M. Vera, Juan F. Watanabe, Norihiro
Published in
Journal for ImmunoTherapy of Cancer
BackgroundPre-clinical and clinical studies have shown that the infusion of CAR T cells with a naive-like (TN) and central memory (TCM) phenotype is associated with prolonged in vivo T cell persistence and superior anti-tumor effects. To optimize the maintenance of such populations during the in vitro preparation process, we explored the impact of ...
Fang, Douglas D. Tang, Qiuqiong Kong, Yanhui Wang, Qixin Gu, Jiaxing Fang, Xu Zou, Peng Rong, Tao Wang, Jingwen Yang, Dajun
...
Published in
Journal for ImmunoTherapy of Cancer
BackgroundProgrammed death-1 (PD-1) immune checkpoint blockade has achieved clinical successes in cancer therapy. However, the response rate of anti-PD-1 agents remains low. Additionally, a subpopulation of patients developed hyperprogressive disease upon PD-1 blockade therapy. Combination therapy with targeted agents may improve immunotherapy. Rec...
Taylor, Molly A. Hughes, Adina M. Walton, Josephine Coenen-Stass, Anna M. L. Magiera, Lukasz Mooney, Lorraine Bell, Sigourney Staniszewska, Anna D. Sandin, Linda C. Barry, Simon T.
...
Published in
Journal for ImmunoTherapy of Cancer
BackgroundThe ability to modulate immune-inhibitory pathways using checkpoint blockade antibodies such as αPD-1, αPD-L1, and αCTLA-4 represents a significant breakthrough in cancer therapy in recent years. This has driven interest in identifying small-molecule-immunotherapy combinations to increase the proportion of responses. Murine syngeneic mode...
Pinato, David J. Gramenitskaya, Daria Altmann, Daniel M. Boyton, Rosemary J. Mullish, Benjamin H. Marchesi, Julian R. Bower, Mark
Published in
Journal for ImmunoTherapy of Cancer
Sensitivity to immune checkpoint inhibitor (ICPI) therapy is governed by a complex interplay of tumor and host-related determinants. Epidemiological studies have highlighted that exposure to antibiotic therapy influences the probability of response to ICPI and predict for shorter patient survival across malignancies. Whilst a number of studies have...
Duong, Minh Ngoc Erdes, Efe Hebeisen, Michael Rufer, Nathalie
Published in
Journal for ImmunoTherapy of Cancer
BackgroundAffinity-optimized T cell receptor (TCR)-engineered lymphocytes targeting tumor antigens can mediate potent antitumor responses in cancer patients, but also bear substantial risks for off-target toxicities. Most preclinical studies have focused on T cell responses to antigen-specific stimulation. In contrast, little is known on the regula...
Ramachandran, Indu Lowther, Daniel E. Dryer-Minnerly, Rebecca Wang, Ruoxi Fayngerts, Svetlana Nunez, Daniel Betts, Gareth Bath, Natalie Tipping, Alex J. Melchiori, Luca
...
Published in
Journal for ImmunoTherapy of Cancer
BackgroundGene-modified autologous T cells expressing NY-ESO-1c259, an affinity-enhanced T-cell receptor (TCR) reactive against the NY-ESO-1-specific HLA-A*02-restricted peptide SLLMWITQC (NY-ESO-1 SPEAR T-cells; GSK 794), have demonstrated clinical activity in patients with advanced synovial sarcoma (SS). The factors contributing to gene-modified ...
Vaishampayan, Ulka Schöffski, Patrick Ravaud, Alain Borel, Christian Peguero, Julio Chaves, Jorge Morris, John C. Kotecki, Nuria Smakal, Martin Zhou, Dongli
...
Published in
Journal for ImmunoTherapy of Cancer
BackgroundAntibodies targeting programmed death-1 (PD-1) or programmed death-ligand 1 (PD-L1) have shown clinical activity in the treatment of metastatic renal cell carcinoma (mRCC). This phase Ib cohort of the JAVELIN Solid Tumor trial assessed the efficacy and safety of avelumab (anti–PD-L1) monotherapy in patients with mRCC as either first-line ...
